SOX2 Recombinant Monoclonal Antibody

說明書

中文名稱：

SOX2重組抗體
貨號(hào)：

CSB-RA973770A0HU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in: U-251 whole cell lysate, MCF-7 whole cell lysate, Mouse Brain whole cell lysate, Rat Brain whole cell lysate
All lanes: SOX2 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 35 kDa
Observed band size: 40 kDa

IHC image of CSB-RA973770A0HU diluted at 1:100 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA973770A0HU SOX2重組單克隆抗體是針對(duì)SOX2轉(zhuǎn)錄因子開發(fā)的高特異性科研試劑，經(jīng)ELISA、免疫印跡（WB）及免疫組化（IHC）多平臺(tái)驗(yàn)證，適用于檢測(cè)內(nèi)源性SOX2蛋白表達(dá)。該抗體在WB實(shí)驗(yàn)中推薦使用1:500至1:5000的寬范圍稀釋梯度，可清晰識(shí)別目標(biāo)條帶；IHC應(yīng)用時(shí)建議1:50-1:200稀釋比例，能有效定位組織樣本中SOX2的亞細(xì)胞分布。SOX2作為維持干細(xì)胞多能性和胚胎發(fā)育的核心調(diào)控因子，在神經(jīng)發(fā)育及腫瘤發(fā)生中具有重要作用，尤其在癌癥干細(xì)胞研究中被視為關(guān)鍵標(biāo)志物。本產(chǎn)品可為干細(xì)胞生物學(xué)、神經(jīng)發(fā)育機(jī)制及腫瘤微環(huán)境研究提供可靠工具，適用于細(xì)胞模型、組織切片等實(shí)驗(yàn)體系中的蛋白表達(dá)分析及功能探索，為探索SOX2在細(xì)胞命運(yùn)調(diào)控及疾病關(guān)聯(lián)中的分子機(jī)制提供精準(zhǔn)檢測(cè)支持。
Uniprot No.：

P48431
基因名：

SOX2
別名：

Transcription factor SOX-2, SOX2
反應(yīng)種屬：

Human, Mouse, Rat
免疫原：

A synthesized peptide derived from human SOX2
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

2E1
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Binds to the proximal enhancer region of NANOG. Critical for early embryogenesis and for embryonic stem cell pluripotency. Downstream SRRT target that mediates the promotion of neural stem cell self-renewal. Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation. May function as a switch in neuronal development.
基因功能參考文獻(xiàn)：
1. SOX2 role in the squamous cancer progression.CCAT1 is a key target co-regulated by TP63 and SOX2 through a super-enhancer in squamous cancer cells. PMID: 30190462
2. Results demonstrated that SOX2 is a target of miR200c in MCF7/Tax cells. Knockdown of SOX2 expression increased chemosensitivity to paclitaxel and upregulated miR200c expression in MCF7/Tax cells. PMID: 30272330
3. BCL11A is integral to lung squamous cell carcinoma pathology and highlights the disruption of the BCL11A-SOX2 transcriptional programme as a novel candidate for drug development. PMID: 30127402
4. Hedgehog signaling (HH) and SOX2 function are inclined to developmental cues and arbitrating malignant growth in prostate cancer. SOX2 inhibition reduces cell proliferation and induces apoptosis. Conjoint inhibition of SOX2 and HH pathway induce apoptosis, reduce proliferation and migration. PMID: 27816521
5. The results remind us that clinical anophthalmia may be accompanied by sensorineural hearing loss and may be associated with SOX2 mutation, and it will contribute to improving diagnosis and patient care. PMID: 30262714
6. Metastatic double primary endometrioid endometrial and ovarian carcinoma sections expressed a higher level of SOX2 compared to the corresponding DPEEOC tissues. PMID: 29569698
7. The invasion and migration of osteosarcoma cells were down-regulated significantly through the inhibition of Sox2 by inactivating Wnt/beta-catenin signaling pathway related proteins PMID: 29619662
8. SOX2 is a critical oncogene linked to cancer stemness properties in urothelial carcinoma of the bladder. PMID: 29180467
9. Six SOX2 positive synovial sarcoma cases were analyzed by FISH using a SOX2/CEN3 dual color FISH probe PMID: 29773426
10. Tumor tissue Sox2 expression was not positively correlated with histologic grade, pathological tumor size and prognosis in surgical patients with triple-negative breast cancer. PMID: 29536377
11. Study in glioma stem-like cells (GSCs) identified SOX2 as one of downstream METTL3 targets and further recruitment of HuR onto m6A-modified sites in SOX2 is essential for SOX2 mRNA stabilization. METTL3 alters the DNA repair efficiency and radiation sensitivity partially via SOX2 in GSCs. PMID: 28991227
12. Myeloid Zinc Finger 1 and GA Binding Protein Co-Operate with Sox2 in Regulating the Expression of Yes-Associated Protein 1 in Cancer Cells PMID: 28905448
13. Human cytomegalovirus IE1 causes SOX2 downregulation by promoting the nuclear accumulation and inhibiting the phosphorylation of STAT3, a transcriptional activator of SOX2 expression. PMID: 29950413
14. hypopharyngeal squamous cell carcinomas characteristically almost completely lacking SOX2 expression appeared to be aggressive neoplasms with high recurrence rates. Promoter hypermethylation was determined to be a major mechanism underlying epigenetic SOX2 silencing PMID: 29143365
15. this study shows that basaloid squamous cell carcinoma and basal cell carcinoma of the head and neck can be readily distinguished by a limited panel consisting primarily of EMA, and supported by SOX2 and p16 PMID: 27438511
16. Results show that the levels of small nucleolar RNA host gene 5 (SNHG5) and SRY (sex determining region Y)-box 2 protein (SOX2) were significantly downregulated in osteoarthritis (OA) tissues, while the level of miR-26a was upregulated. PMID: 29409014
17. SOX2 copy number increases are detectable in a substantial proportion of high-grade HPV-positive vulvar carcinomas with basaloid differentiation. PMID: 28700423
18. The staining patterns did not reliably distinguish cervical intraepithelial neoplasia, grade 3 (CIN 3) from CIN 3-like Squamous cell carcinoma (SCC). Small infiltrative tumor nests around the margins of CIN 3 or deeply invasive CIN 3-like SCC often showed a localized reduction in SOX2 expression suggesting SOX2 downregulation during the transition to invasive growth. PMID: 28319578
19. Low SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage PMID: 29596469
20. SOX2 overexpression in DPSCs promoted the regulation of odontoblast differentiation of DPSCs PMID: 29039570
21. SOX2 expression is dependent on contact with enhancers 700 kb downstream via CTCFdependent chromatin looping. PMID: 29091765
22. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients, it regulates osteosarcoma cells proliferation and motility through SOX2 modulation, and is correlated with patients' survival. PMID: 28960757
23. SOX2 overexpression is associated with cancer. PMID: 29587142
24. Histone acetyltransferase EP300 is necessary for the transcription factor SOX2 activity in basal cells, including for induction of the squamous fate. EP300 copy number gains are common in squamous cell carcinoma SQCCs, including lung cancer SQCC cell lines. PMID: 28794006
25. NFATc2 enhances tumor-initiating phenotypes through the NFATc2/SOX2/ ALDH1A1 axis in lung adenocarcinoma. PMID: 28737489
26. Block the activation of the VRK1 promoter by Sox2. PMID: 27334688
27. Heterozygous loss-of-function mutations in SOX2 are the commonest cause of severe microphthalmia and anophthalmia. PMID: 28635421
28. This data demonstrated immunogenicity of SOX2, which is specifically overexpressed on pediatric glial tumor cells. PMID: 28620836
29. OCT4 and SOX2 work as transcriptional activators in reprogramming human fibroblasts. PMID: 28813671
30. Sox2-expressing cells mark a subpopulation of tumor cells that fuel the growth of established BCa. SOX2-positive cells also expressed other previously reported BCa CSC markers, including Keratin14 (KRT14) and CD44v6. Ablation of Sox2-expressing cells within primary invasive BCa led to enhanced tumor regression PMID: 28793245
31. studies on the role of SOX2 in breast cancer may provide effective biomarkers and potential therapeutic targets for the diagnosis and treatment of breast cancer PMID: 28674712
32. In conclusion, targeted sequencing for SOX2 and VSX2 identified the etiology in two patients (7.4%) and this is the first report of SOX2 mutation from Egypt. PMID: 28121235
33. Kat2b are essential to the differentiation through enhancing recruitment neuroectodermal factors Sox2 and Pax6 to their target sites. PMID: 28475175
34. combined administration of small-interfering RNA (siRNA) transfection with PPARgamma ligands induced downregulation of SOX2 and MMP2 activity together with inhibition of sphere-forming activity regardless of poly(ADP-ribose) polymerase (PARP) cleavage. Taken together, our findings suggest that a combination therapy using PPARgamma ligands and its inhibitor could be a potential therapeutic strategy targeting glioblastom... PMID: 28642874
35. DDX53 directly regulates the SOX-2 expression in drug-resistant melanoma cells. PMID: 28535666
36. Rectal tumor tissue OCT4 (p<0.001), SOX2 (p=0.003), and NANOG (p<0.001) expressions were higher than those in adjacent tissue. PMID: 29214774
37. Thus, SOX2 is a master regulator of the acinar cell lineage essential to the establishment of a functional organ. PMID: 28623666
38. Results provide evidence that SOX2 expression is regulated by the transcription factor HSF1. PMID: 29316077
39. SOX2 overexpression and the loss of Rb1 protein expression might have a pivotal role in the divergent differentiation of pluripotent embryonic-like epithelial cells and the development of esophageal small-cell carcinoma. PMID: 28106103
40. In SOX2-deficient cells, BMP signaling is inhibited, but NODAL signaling is not activated. Thus, SOX2 appears to be downstream of BMP signaling but upstream of NODAL activation. PMID: 27283990
41. Results show lower SOX2 in the lymph node metastases from head and neck squamous cell carcinomas (HNSCCs) and in cervical cancer of unknown primary patients compared with the primary tumor. Tumors from N1 to N3 stage exhibit decreasing SOX2 expression in the lymphatic metastases. Its expression is showed to be involved in the proliferation and migration of HNSCC cell lines. PMID: 28002801
42. SOX2 overexpression could be used as a positive prognostic factor in patients with stage III lung squamous cell carcinoma receiving adjuvant radiotherapy PMID: 26323639
43. The survival rate was increased by 11.1% in Oct4/Sox2-hAT-MSC-injected mice. PMID: 28438862
44. hypoxia-NOTCH1-SOX2 signaling axis is important for activation of ovarian cancer stem cells. PMID: 27489349
45. This severe movement disorder appears to be a feature of some types of SOX2-anophthalmia syndrome thus expanding the phenotype. We strongly recommend that all newborns with bilateral anophthalmia/microphthalmia be screened for mutations in SOX2 PMID: 27427475
46. Findings indicate that long-term exposure to IM results in dysregulation of stem cell renewal-regulatory Hippo (MST1/2)/YAP signaling, and that inhibition of miR-181a using a microRNA sponge inhibitor resulted in decreased transcription of SOX2 and SALL4. PMID: 28103766
47. The authors found that high/positive SOX2 alterations, either DNA amplification or protein expression, were favorable for overall survival (OS) in non-small cell lung cancer. On the contrary, high/positive Nestin protein expression was poor for OS. PMID: 27150062
48. Data show that tunicamycin reduces the expression of self-renewal regulator Sox2 at translation level. PMID: 27119230
49. Increasing SOX2 reduces growth inhibition mediated by MEK and AKT inhibitors; whereas knockdown of SOX2 further reduces growth when Pancreatic ductal adenocarcinoma cells are treated with these inhibitors. Thus, targeting SOX2, or its mode of action, could improve the treatment of Pancreatic ductal adenocarcinoma. PMID: 27145457
50. This study discloses novel SOX2 target genes driving neuroendocrine differentiation and spread of PC and proposes SOX2 as a functional biomarker of LN metastasization for prostate cancer. PMID: 26540632
顯示更多

收起更多
相關(guān)疾病：

Microphthalmia, syndromic, 3 (MCOPS3)
亞細(xì)胞定位：

Nucleus.
數(shù)據(jù)庫(kù)鏈接：

HGNC: 11195

OMIM: 184429

KEGG: hsa:6657

STRING: 9606.ENSP00000323588

UniGene: Hs.518438

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human